Aravax's Monthly Peptide Therapy PVX108 More Than Doubled the Peanut Dose Allergic Children Could Tolerate in Phase 2
In children aged 4 to 11, the maximum tolerated peanut dose after 12 months rose 2.4-fold on PVX108 50 nmol (23 children) versus 1.2-fold on placebo (24 children), Aravax said, and 39.4% versus 16.7% tolerated a cumulative 443 mg of peanut protein. The company reported no treatment-related allergic reactions or anaphylaxis. The monthly injection uses peptides designed to retrain T cells to tolerate peanut. Results from the 14-site U.S. and Australian trial are company-reported ahead of a November 14 presentation at the ACAAI meeting in Phoenix.